Novel method results in promising drugs for Huntington's disease therapeutics

January 26, 2011

Huntington's disease (HD) is an incurable progressive neurodegenerative genetic disorder which affects motor coordination and leads to cognitive decline and dementia.

The disease pathology stems from a mutation in the huntingtin (Htt) gene which results in the accumulation of toxic proteins leading to . Earlier studies have clearly implicated caspases, enzymes that break down cells, as key players in the cascade of events involved in HD neuronal death. Now scientists have identified three small molecules that inhibit the activity of those caspases, suppressing toxicity and rescuing neurons from cell death in cell culture.

The research, which appears in the November 24th edition of , was led by both Buck Institute faculty member Lisa Ellerby, Ph.D. and Yale University faculty member Jonathan Ellman, Ph.D. Dr. Ellerby is doing follow up studies in a mouse model of the disease.

Dr. Ellerby said a substrate based was used to identify compounds that reacted with caspases. Based on those reactions, Jonathan Ellman, Ph.D., from the Yale University Department of Chemistry, converted the compounds to caspase inhibitors.

Dr. Ellerby said that the inhibitors are based on properties of a drug which had entered Phase I clinical trials for the treatment of human liver preservation injury. "These molecules shows particular promise," said Ellerby. "They cross the blood-brain barrier and acts selectively to block the processes involved in HD." Dr. Ellerby said the caspase inhibitors both suppressed the proteolysis of Htt and rescued HD neurons that have begun to undergo cell death.

"We believe this is going to help us move the field forward because now we can test these compounds in live animals," said Dr. Ellerby. "Up until this point we have not identified a caspase inhibitor that has acted selectively against the toxic effects of the Htt mutation."

There is a desperate need for a treatment for HD. Symptoms of the disease usually begin to occur in middle age; patients are often totally incapacitated prior to death. The worldwide prevalence of HD is 5-10 cases per 100,000 people; the rate of occurrence is highest in peoples of Western European descent.

Explore further: Study identifies potential drug target for Huntington's disease

Related Stories

Protecting the brain from a deadly genetic disease

February 23, 2010

Huntington's disease (HD) is a cruel, hereditary condition that leads to severe physical and mental deterioration, psychiatric problems and eventually, death. Currently, there are no treatments to slow down or stop it. ...

Research links huntingtin to neurogenesis

August 11, 2010

New research finds that a protein that is often mutated in Huntington's disease (HD) plays an unexpected role in the process of neurogenesis. The research, published by Cell Press in the August 12 issue of the journal Neuron, ...

Protein in Huntington's linked to neurogenesis

September 2, 2010

EU-funded scientists have discovered that a mutated protein inherent in Huntington's disease (HD) performs an unforeseen role in neurogenesis. The finding could lead to a better understanding of HD, an inherited neurodegenerative ...

Recommended for you

How the finch changes its tune

August 3, 2015

Like top musicians, songbirds train from a young age to weed out errors and trim variability from their songs, ultimately becoming consistent and reliable performers. But as with human musicians, even the best are not machines. ...

Machine Translates Thoughts into Speech in Real Time

December 21, 2009

( -- By implanting an electrode into the brain of a person with locked-in syndrome, scientists have demonstrated how to wirelessly transmit neural signals to a speech synthesizer. The "thought-to-speech" process ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.